Quick-Med Technologies, a life sciences company, has received an approval from the patent office of Mexico, Instituto Mexicano de la Propiedad Industrial (IMPI), for its new patent that expands the international intellectual property coverage of the company's Nimbus technology.
The Mexico patent, which is titled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate", remains in effect until 22 August 2026.
The method of production that non-leachably bonds Nimbus antimicrobials to various treated substrates has been covered under the new patent.
Nimbus is an antimicrobial technology that has been custom designed for wound care and other medical applications, and it is protected by 12 US patents.
Quick-Med vice president of Research & Development, Dr. Jerry Olderman said the company's non-leachable bonding of the antimicrobial agent distinguishes Nimbus from other antimicrobial materials which require release of the active agent in order to function.
"This patent covers the process of treating materials such that they become permanent barriers to the transmission of microorganisms," Olderman said.
It addresses the process of attaching members of the Nimbus family of antimicrobials to substrates that are whole or in part cellulosic or any of a list of other substrates including such polymerics as polyurethane, polyester, nylon and acrylics, as well as silk, linen, rubber, alginates and collagen among many others.
The company was awarded similar patents in the US, Australia, and South Africa but is pending approvals in Canada, China, Europe, India, and Japan.
